​On November 26, 2022, the donation signing ceremony of "Peking University Baheal Medical Science and Technology Innovation and Achievement Transformation Fund" was held at Peking University Health Science Center.

Recently, Qingdao Baheal Medical INC. (Baheal Medical, 301015.SZ) announced the signing of a strategic cooperation agreement with Astrazeneca Investment (China) Co., LTD. ("Astrazeneca China").

Qingdao Baheal Medical INC. (hereinafter referred to as “Baheal Medical”, 301015.SZ) announced that it has obtained the exclusive retail channel promotion rights of Rocaltrol ® (calcitriol soft capsules)---a classic drug for the treatment of osteoporosis---in Chinese mainland. Roche pharmaceuticals China will continue to be responsible for the promotion of Rocaltrol ® in the hospital market.

On August 16, 2022, Qingdao Baheal Medical INC. (hereinafter referred to as “Baheal Medical”, 301015.SZ) announced the signing of a renewal agreement with Takeda (China) Investment Co., Ltd. (hereinafter referred to as “Takeda China”) in Qingdao, China.

On July 27, 2022, Qingdao Baheal Medical INC. (hereinafter referred to as “Baheal Medical”, 301015.SZ) announced the signing of a deepening strategic cooperation agreement with Xi’an Giant Biogene Holding Co., Ltd. (hereinafter referred to as “Giant Biogene”).